Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Roche has reported a successful Phase 3 study for its KRAS G12C inhibitor, divarasib. The late-stage trial focused on non-small cell lung cancer (NSCLC), where the drug candidate beat existing therapies in head-to-head comparisons.
Coverage from the Wall Street Journal, STAT, and Fierce Biotech emphasizes that Roche's candidate outperformed rivals from Amgen and BMS. Endpoints News and FirstWord PHARMA characterize the results as a win over existing KRAS G12C inhibitors.
Future developments depend on the drug setting a new standard for treating KRAS-driven lung cancer following these trial results.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
What is the name of the drug candidate?
The drug candidate is called divarasib.
Which companies did Roche's drug compete against in the study?
The study involved head-to-head comparisons against rivals from Amgen and BMS.
What specific condition is the drug designed to treat?
It is a KRAS G12C inhibitor used for KRAS-driven non-small cell lung cancer (NSCLC).
Coverage (5)
- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study Endpoints News · 11h ago
- Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS Fierce Biotech · 11h ago
- Roche drug sets new standard for KRAS-driven lung cancer STAT · 11h ago
- Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study FirstWord PHARMA · 11h ago
- Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial WSJ · 11h ago broke it first
People, places & organizations
Topics
Related trends
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into drug trials conducted in China by major pharmaceutical companies, including Merck and AbbVie.
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.